miR-124在结直肠癌的相关研究进展:一个潜在的治疗靶点  

Progress of miR⁃124 in colorectal cancer:a potential therapeutic target

作　　者：张辉 路明亮[1] ZHANG Hui;LU Mingliang(Department of Gastroenterology,the Second Affiliated Hospital,Kunming Medical University,Kunming 650000,China)

机构地区：[1]昆明医科大学第二附属医院消化内科,昆明650000

出　　处：《实用医学杂志》2021年第13期1774-1778,共5页The Journal of Practical Medicine

基　　金：云南省卫生和计划生育委员会医学后备人才培养计划(编号:H⁃201702)。

摘　　要：结直肠癌(colorectal cancer,CRC)是常见的消化系统恶性肿瘤。随着人们生活方式的改变,CRC的发病率和病死率在世界范围内逐年增高,结直肠癌的发生发展机制至今仍不清楚,复发率高、易转移等生物学特性,导致预后差,是目前临床治疗面临的巨大挑战。miR-124可影响结直肠癌的发生发展,在结直肠癌发病机制方面已进行了深入研究;本文对miR-124上游调节分子、下游靶基因及潜在的RNA靶向治疗相关进展作一综述。Colorectal cancer(CRC)is the most common carcinoma in gut.The incidence and mortality of CRC are increasing gradually every year with the changes of people′s life style,but the underlying mechanism is still not completely elucidated.The poor prognosis is due to its high rates of recurrence and metastasis.miR⁃124 has been confirmed to play a vital role in the pathogenesis of CRC.In this review,we summarize the upstream mol⁃ecules and downstream target genes of miR⁃124,and we also discuss the potential target therapy for miR⁃124.

关 键 词：miR-124 结直肠癌 靶向治疗 

分 类 号：R735.3[医药卫生—肿瘤]